STP 144G
Alternative Names: STP-144GLatest Information Update: 03 Apr 2024
At a glance
- Originator Sirnaomics
- Class Peptide drug conjugates; Small interfering RNA
- Mechanism of Action Complement factor B modulators; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Immunological disorders
Most Recent Events
- 28 Mar 2024 Sirnaomics announces intention to file an IND application for STP 144G in the US in 2025
- 26 Aug 2022 Sirnaomics plans a clinical trial for Immunological disorders in second half of 2023
- 29 Sep 2020 Preclinical trials in Immunological disorders in USA (SC) (Sirnaomics pipeline, September 2020)